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Introduction {#sec1}
============

Neural stem cells (NSCs) are located in two main regions of the adult mammalian brain, the dentate gyrus of the hippocampus and the ventricular-subventricular zone (V-SVZ) of the lateral ventricles ([@bib13], [@bib37]). These NSCs reside primarily in a mitotically dormant state known as quiescence. Stimuli including injury and exercise can induce quiescent NSCs to divide and produce new neurons or glia ([@bib29], [@bib30]). By characterizing quiescence regulators, it may become possible to activate quiescent NSCs on demand and regenerate brain tissue following injury or disease ([@bib15]).

Quiescent NSCs vary in their sensitivities or responses to external stimuli, suggesting that they undergo different types of quiescence. For example, "resting" stem cells in the adult mouse hippocampus, which are quiescent NSCs that have proliferated recently, are more likely to become activated than naive quiescent NSCs ([@bib43]). Quiescent progenitors are also differentially responsive to norepinephrine and KCl ([@bib22]). Once activated, quiescent NSCs in the brain generate different types of progeny in a region-specific manner ([@bib17]). Single-cell profiling has revealed transcriptional and metabolic heterogeneity in quiescent NSCs, linked to priming for activation and regional identity ([@bib14], [@bib29], [@bib38]). Although it is now appreciated that quiescent NSCs exhibit significant heterogeneity ([@bib7]), the factors that induce stem cells to undergo different types of quiescence in the brain are not understood well.

It has been widely accepted for many years that quiescent stem cells arrest in G~0~ of the cell cycle ([@bib8]). However, we discovered recently that NSCs in the *Drosophila melanogaster* central nervous system undergo two distinct types of quiescence: 75% of NSCs arrest in G~2~ of the cell cycle and only 25% arrest in G~0~ ([@bib34]). G~2~-quiescent NSCs activate rapidly in response to a nutritional stimulus, while G~0~-quiescent NSCs respond more slowly ([Figure 1](#fig1){ref-type="fig"}A) ([@bib34]). Thus, G~2~ and G~0~ NSCs are functionally distinct types of quiescent stem cell. We showed that NSCs are pre-programmed to undergo G~0~ or G~2~ quiescence in an invariant manner ([@bib34]). An understanding of the differential regulation of G~0~/G~2~ quiescence should reveal the factors that trigger different types of stem cell quiescence.Figure 1p57/Dap Is Necessary for G0 NSC Quiescence(A) NSC behaviors during *Drosophila* development. NSCs become quiescent in G~0~ (red) or G~2~ (cyan) in the late embryo. G~2~-quiescent NSCs reactivate before G~0~-quiescent NSCs post-embryonically. The factors that determine arrest in G~0~ or G~2~ are not known.(B) A single hemi-segment of a control brain. 26% ± 1.0% of NSCs are G~0~ quiescent (CycA^−^; red; circled), and 75% ± 1.0% are G~2~ quiescent (CycA^+^; cyan). Dotted line indicates ventral midline. Maximum intensity projection. *n* = 10 tVNCs, ∼135 NSCs each.(C) In control brains, two out of three NSCs in the dorsal triplet arrest in G~0~ (red; arrowed) and one in G~2~ (cyan). Single section image.(D) A single hemi-segment of a *dap* mutant brain. 2% ± 0.4% of NSCs are G~0~ quiescent and 98% ± 0.4% are G~2~ quiescent. Maximum intensity projection. *n* = 10 tVNCs, ∼135 NSCs each. The percentage of G~0~-quiescent NSCs is significantly different to controls. ^∗∗∗^p = 1.19 × 10^−14^, Student's t test. Dotted line indicates ventral midline.(E) In *dap* mutant brains, all three NSCs in the dorsal triplet arrest in G~2~ (cyan). *n* = 10 tVNCs. Single section image.Anterior is up, and dorsal is right in all images.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Here, we demonstrate that the cyclin-dependent kinase inhibitor p57/Dap directs NSCs to enter G~0~ quiescence, rather than G~2~ quiescence, during embryogenesis. Upon loss of *p57*/*dap*, NSCs switch from G~0~ to G~2~ quiescence and, as a result, reactivate more rapidly in response to nutrition post-embryonically. We found that G~0~ NSCs primarily occupy dorsal regions of the central nervous system and that G~2~ NSCs primarily occupy ventral regions, suggesting that dorsal-ventral patterning cues might influence *p57*/*dap* expression and consequently the choice between G~0~ or G~2~ stem cell quiescence. We discovered that the dorsal patterning transcription factor Muscle segment homeobox (Msh, also known as Drop/Dr---Flybase) promotes G~0~ quiescence by inducing *p57*/*dap* expression in a subset of dorsal NSCs. *msh* and *p57/dap* are evolutionarily conserved, suggesting that a similar region-specific mechanism might induce different types of stem cell quiescence in the mammalian brain.

Results {#sec2}
=======

Dap Is Necessary for G~0~ Quiescence {#sec2.1}
------------------------------------

The factors that regulate the choice between G~0~ and G~2~ quiescence in NSCs at the end of embryogenesis are not known ([Figure 1](#fig1){ref-type="fig"}A). We hypothesized that p57/Dap regulates G~0~ stem cell quiescence, as it is the sole *Drosophila* ortholog of the evolutionarily conserved p21^CIP^/p27^KIP1^/p57^KIP2^ family of cyclin-dependent kinase inhibitors capable of blocking G~0~/G~1~\>S progression in the cell cycle ([@bib12], [@bib27]). We assessed quiescent NSCs in the loss-of-function mutant *dap*^*04454*^ ([@bib12], [@bib41]) using cyclin A (CycA) expression to distinguish between G~0~ (CycA^−^) and G~2~ (CycA^+^) quiescence, as described previously ([@bib34]). We focused on the thoracic segments of the ventral nerve cord (tVNC), a region of the central nervous system in which individual NSCs can be identified readily based on spatial position and molecular markers ([@bib26]). Remarkably, we found that G~0~-quiescent NSCs had almost completely disappeared in *dap* mutant tVNCs ([Figures 1](#fig1){ref-type="fig"}B and 1D). *dap* mutants had an average of 0.6 ± 0.1 G~0~ NSCs per hemi-segment, compared to 7.2 ± 0.2 G~0~ NSCs per hemi-segment in controls (92% reduction, *n* = 10 tVNCs, 6 hemi-segments each).

The loss of G~0~ NSCs might be due to cell death or premature differentiation. However, we found no change in the total number of NSCs in *dap* mutants (*n* = 136 ± 2.7 NSCs versus 136 ± 4.0 NSCs, 10 tVNCs each, p \> 0.05, Student's t test). We hypothesized that the G~0~ NSCs might instead have switched to G~2~ quiescence. To test this, we focused on quiescent NSCs in the "dorsal triplet," a group of three NSCs (NB2-4, NB2-5, and NB3-5) that can be discriminated unambiguously based on their spatial location in the tVNC ([@bib26]). NB2-4 and NB2-5 in the dorsal triplet normally undergo G~0~ quiescence, while NB3-5 arrests in G~2~ ([Figure 1](#fig1){ref-type="fig"}C) ([@bib34]). In *dap* mutant brains, we found that NB2-4 and NB2-5 switched from G~0~ quiescence to G~2~ quiescence, leading to all dorsal triplet NSCs arresting in G~2~ ([Figure 1](#fig1){ref-type="fig"}E). We observed a similar reduction in G~0~-quiescent NSCs and increase in G~2~-quiescent NSCs when we knocked down *dap* specifically in NSCs throughout embryogenesis using the *worniu* (*wor*)-GAL4 driver ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib1]). We conclude that Dap is necessary for G~0~ NSC quiescence and that Dap is required autonomously in NSCs.

We showed previously that G~2~ NSCs become activated more rapidly than G~0~ NSCs in response to nutrition ([@bib34]). Therefore, we tested whether *dap* knockdown caused "G~0~" NSCs to reactivate at the same rate as G~2~ NSCs. We assessed NSC activation at 20 h after larval hatching (ALH), a time point when, in control brains, most G~2~ NSCs have reactivated but most G~0~ NSCs remain quiescent ([@bib34]). We found a substantial increase in the number of NSCs that had reactivated by 20 h ALH in *dap* knockdown brains compared to controls ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Thus, the switch from G~0~ to G~2~ quiescence after *dap* knockdown is sufficient to accelerate the time at which NSCs reactivate.

G~0~ NSCs Express Dap Prior to Quiescence Entry {#sec2.2}
-----------------------------------------------

Next, we assessed the timing of Dap expression in NSCs. The levels of Dap oscillate during the cell cycle ([@bib2]); therefore, to assess Dap transcription, we used a transcriptional reporter in which *lacZ* is inserted at the *dap* locus (hereafter "*dap*::*lacZ*"; [@bib40]). Importantly, β-galactosidase is stable, and its abundance is not regulated by the cell cycle. We observed a subset of NSCs expressing *dap* prior to quiescence entry ([Figure 2](#fig2){ref-type="fig"}A) and, by co-staining for CycA, found that *dap* expression is almost entirely specific to G~0~ NSCs. 89% of G~0~ NSCs (6.4 ± 0.3 out of 7.2 ± 0.3 per hemi-segment) expressed *dap::lacZ* in contrast to 13% of G~2~ NSCs (2.6 ± 0.2 out of 19.7 ± 0.7 per hemi-segment) ([Figure 2](#fig2){ref-type="fig"}B). Typifying this pattern, the two G~0~ NSCs of the dorsal triplet (NB2-4 and NB2-5) expressed *dap::lacZ* but not the G~2~ NSC (NB3-5) ([Figure 2](#fig2){ref-type="fig"}C).Figure 2p57/Dap Is Expressed in G~0~ NSCs(A) A single hemi-segment of a tVNC co-stained to visualize NSCs (red) and dap::lacZ (green). *dap*::lacZ^+^ NSCs are circled. Dotted line indicates ventral midline. Maximum intensity projection. See [STAR Methods](#sec4){ref-type="sec"} for explanation of the "dorsal" and "ventral" designations.(B) Percentages of G~0~- and G~2~-quiescent NSCs that express *dap::lacZ*. *n* = 7 tVNCs, ∼135 NSCs each. ^∗∗∗^p = 6.10 × 10^−14^, Student's t test. Red lines indicate medians.(C) *dap::lacZ* (green) is expressed in the two G~0~ NSCs of the dorsal triplet (arrowed) but not the G~2~ NSC.Anterior is up, and dorsal is right in all images.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Once NSCs enter quiescence, we found that they no longer transcribe or translate Dap ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). Thus, G~0~ NSCs express Dap in the embryo but downregulate its expression concomitant with quiescence entry.

G~0~- and G~2~-Quiescent NSCs Are Distributed in a Dorsal-Ventral Gradient {#sec2.3}
--------------------------------------------------------------------------

NSCs acquire their identities through spatial patterning in the developing nervous system. Therefore, the decision to undergo G~0~ or G~2~ quiescence might be influenced by spatial positioning. By comparing the distributions of G~0~ and G~2~ NSCs in the tVNC, we noticed a bias toward G~0~ NSCs in dorsal regions and G~2~ NSCs in ventral regions. In contrast, we found no bias along the anterior-posterior axis ([Figures 3](#fig3){ref-type="fig"}A and 3B). This suggested that dorsal-ventral patterning cues might influence *dap* expression and G~0~ quiescence entry.Figure 3G~0~ NSCs Are Prevalent in the Dorsal Nervous System(A) The distribution of G~0~-quiescent NSCs (red) and G~2~-quiescent NSCs (cyan) in each hemi-segment of the tVNC. Dotted line indicates ventral midline. G~0~ NSCs are prevalent in dorsal regions, and G~2~ NSCs in ventral regions. A, anterior; P, posterior. G~0~ and G~2~ NSCs according to [@bib34].(B) A single hemi-segment of a tVNC in the same orientation and colors as in (A). G~0~ NSCs are circled. Dotted line indicates ventral midline. To enable comparison with (A), the G~0~ NSCs NB2-2 and NB3-4 are indicated. Maximum intensity projection.(C) Comparison of the numbers of G~0~- *versus* G~2~-quiescent NSCs per hemi-segment in ventral (Vnd^+^), intermediate (Ind^+^), and dorsal (Msh^+^) regions. Data assembled using data from [@bib9], [@bib11], [@bib20], [@bib33]; and [@bib45].(D) The same tVNC hemi-segment as in (B), with Msh-expressing regions labeled in green using G-TRACE. G~0~ NSCs are circled. Most G~0~ NSCs reside in the Msh^+^ domain. To enable comparison with (A), the G~0~ NSCs NB2-2 and NB3-4 (that do not express Msh) are indicated. Maximum intensity projection.Anterior is up, and dorsal is right in all images.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

The dorsal-ventral axis of the tVNC is patterned during embryogenesis by three conserved homeobox transcription factors expressed in adjacent columns of the neuroectoderm: *msh* (dorsal identity; human orthologs: MSX1/2/3), *intermediate neuroblasts defective* (*ind*; intermediate identity; human orthologs: GSX1/2), and *ventral nervous system defective* (*vnd*; ventral identity; human orthologs: NKX family) ([@bib9], [@bib11], [@bib20], [@bib33], [@bib45]). When NSCs delaminate from the neuroectoderm, they continue to express either Msh, Ind, or Vnd, depending upon their position along the dorsoventral axis. The only exceptions to this rule are NB3-3, NB3-5, and NB4-4, which delaminate from the Msh^+^ domain but do not themselves express *msh* ([@bib20]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

By aligning our G~0~/G~2~ quiescence map with the Msh/Ind/Vnd expression domains, we found that 5 of 7 Msh^+^ (dorsal) NSCs per hemi-segment undergo G~0~ quiescence, compared to just 1 of 9 Vnd^+^ (ventral) NSCs ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}A). We confirmed that most G~0~ NSCs originate in the dorsal Msh^+^ domain by using *msh*-GAL4 (driven by a ∼3.5 kb fragment upstream of *msh*) to express GAL4 technique for real-time and clonal expression (G-TRACE) ([@bib16]). We found that an average of 4.2 ± 0.1 out of 7.7 ± 0.2 G~0~ NSCs per hemi-segment were Msh \> G-TRACE^+^ (*n* = 8 tVNCs, 6 hemi-segments each) ([Figure 3](#fig3){ref-type="fig"}D; compare to 3B). We obtained the same number when we labeled Msh^+^ NSCs using a *lacZ* insertion at the *msh* locus ([@bib20]) (4.2 ± 0.2 out of 7.4 ± 0.4 G~0~ NSCs per hemi-segment, *n* = 5 tVNCs, 6 hemi-segments each). Thus, many G~0~ NSCs are Msh^+^ NSCs originating in dorsal regions of the tVNC.

The Dorsal Patterning Factor Msh Promotes G~0~ Quiescence {#sec2.4}
---------------------------------------------------------

To test whether Msh promotes G~0~ quiescence, we quantified G~0~- *versus* G~2~-quiescent NSCs in *msh* mutant brains at embryonic stage 17. We found that only 3.7 ± 0.1 G~0~-quiescent NSCs remained per hemi-segment in *msh*^*Δ68*^ mutants compared to 6.3 ± 0.3 in controls (41% reduction; *n* = 10 tVNCs, 6 hemi-segments each) ([Figure S3](#mmc1){ref-type="supplementary-material"}B). G~0~ NSCs had not died or differentiated in *msh* mutants, as the total number of NSCs was the same as in controls (*n* = 136 ± 3.1 NSCs versus 134 ± 6.2 NSCs, p \> 0.05, Welch's test). This indicated that a subset of NSCs switches from G~0~ to G~2~ quiescence in *msh* mutants, as occurs in *dap* mutants.

As Msh is necessary for dorsal patterning ([@bib20]), we surmised that dorsal (but not ventral) NSCs switch from G~0~ to G~2~ quiescence in *msh* mutants. To test this, we focused again on dorsal triplet NSCs, as they are three of the most dorsally located NSCs in the tVNC ([@bib26]). The two G~0~ NSCs in the dorsal triplet (NB2-4 and NB2-5) express *msh*, whereas the G~2~ NSC (NB3-5) does not ([Figure 4](#fig4){ref-type="fig"}A). In *msh* mutant brains, we found that NB2-4 and NB2-5 switched from G~0~ quiescence to G~2~ quiescence, resulting in all three dorsal triplet NSCs becoming quiescent in G~2~ ([Figure 4](#fig4){ref-type="fig"}B). Thus, Msh promotes G~0~ quiescence in dorsal NSCs. As a comparison, we assessed a G~0~ NSC on the ventral side of the tVNC (NB2-2), which never expresses Msh normally. As expected, NB2-2 remained G~0~ arrested in *msh* mutants ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Thus, Msh promotes G~0~ quiescence in dorsal, but not ventral, NSCs.Figure 4Msh Induces G~0~ Quiescence by Directly Promoting p57/Dap Expression(A) *msh*::lacZ (green) is expressed in both G~0~ NSCs (arrowed) of the dorsal triplet but not in the G~2~ NSC.(B) In *msh* mutants, all NSCs in the dorsal triplet arrest in G~2~ quiescence (cyan). Arrows indicate G~0~ NSCs in controls.(C) Quantification of Dap^+^ NSCs in control (*msh*^*Δ68*^ heterozygous) versus *msh*^*Δ68*^ mutant brains at embryonic stage 13. Dap expression was assessed using anti-Dap antiserum. *n* = 6 tVNCs/genotype, ∼140 NSCs each. ^∗∗^p = 1.36 × 10^−3^, Student's t test. Red lines indicate medians. Blue data point is an outlier.(D) Msh binding at the *dap* locus, assessed specifically in embryonic NSCs using TaDa ([@bib39]). Unlogged data assembled from three biological replicates. Orange bars indicate enhancers that were characterized functionally to drive *dap* expression in the central nervous system ([@bib28]).(E) Model for dorsal-ventral control of stem cell quiescence. The dorsal patterning factor Msh directly induces *dap* expression in dorsal NSCs, causing them to undergo the type 1 \> 0 proliferation switch, followed by arrest in G~0~ quiescence. Ventral NSCs do not express Msh or Dap, do not undergo type 0 proliferation, and arrest in G~2~ quiescence.Anterior is up, and dorsal is right in all images.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

We tested whether the ventral patterning factor Vnd also has the ability to promote G~0~ quiescence in the tVNC. NB2-2 is the only Vnd^+^ NSC per hemi-segment that undergoes G~0~ quiescence ([Figure S3](#mmc1){ref-type="supplementary-material"}A). In *vnd*^*6*^ mutants, we found that NB2-2 did not switch from G~0~ to G~2~ quiescence ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E′). We conclude that Vnd does not promote G~0~ quiescence ventrally.

Msh Directly Induces *Dap* Expression in Dorsal NSCs {#sec2.5}
----------------------------------------------------

Dap and Msh both promote G~0~ stem cell quiescence and could act in a linear pathway. We found that the same NSCs (for example, NB2-4 and NB2-5) co-express Msh and Dap during embryogenesis ([Figures 2](#fig2){ref-type="fig"}C and [4](#fig4){ref-type="fig"}A). We tested whether Msh induces *dap* expression, as NSCs begin to express *msh* from embryonic stage 9/10 while *dap* expression initiates later, from embryonic stage 11 ([@bib2], [@bib12], [@bib20], [@bib27]). Consistent with Msh promoting *dap* expression, we found that dorsal NSCs lost Dap expression in *msh* mutant embryos ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Only 2.6 ± 0.3 NSCs per hemi-segment expressed Dap in *msh* mutant embryos compared to 4.9 ± 0.2 NSCs in controls, a decrease of almost 50% ([Figure 4](#fig4){ref-type="fig"}C). Thus, Msh is one upstream regulator that promotes Dap expression in the central nervous system.

Msh might promote Dap expression in NSCs directly, by binding to the *dap* locus and inducing transcription, or indirectly. The genomic targets of Msh are not known. We therefore elucidated the genome-wide binding targets of Msh in NSCs *in vivo* using Targeted DamID (TaDa) ([@bib31], [@bib32], [@bib39]). We generated transgenic *Drosophila* carrying UAST-LT3-NDam-Msh, which we expressed specifically in NSCs *in vivo* using *wor*-GAL4. We found that Msh binds directly to the *dap* locus in NSCs ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}C). Remarkably, Msh binding at the *dap* locus precisely matched the enhancer sequences previously shown to be sufficient for *dap* expression in the embryonic central nervous system ([@bib28]; [Figure 4](#fig4){ref-type="fig"}D).

We conclude that the dorsal patterning factor Msh binds directly to *dap* enhancers in dorsal NSCs and induces *dap* expression. As Dap promotes G~0~ quiescence, this leads to a preferential distribution of G~0~-quiescent NSCs in dorsal regions of the brain ([Figure 4](#fig4){ref-type="fig"}E). In contrast, Msh is not expressed in ventral regions, where more NSCs undergo G~2~ quiescence ([Figure 4](#fig4){ref-type="fig"}E). G~2~-quiescent NSCs become activated first, followed by G~0~-quiescent NSCs, during larval life ([@bib34]). Thus, differential *dap* expression results directly in functional heterogeneity among quiescent stem cells.

Discussion {#sec3}
==========

Quiescent NSCs in the mammalian brain exhibit significant heterogeneity in function and molecular profile ([@bib14], [@bib29], [@bib38]). In order to harness quiescent NSCs for regenerative therapies, it will be necessary to identify the regulators that control different types of stem cell quiescence. Here, we have identified Msh-p57/Dap as one regulatory arc that induces G~0~ stem cell quiescence in dorsal NSCs of the central nervous system. Together with our previous finding that the pseudokinase Tribbles (Trbl) regulates G~2~ NSCs ([@bib34]), we have elucidated the mechanisms that allocate and regulate NSCs entering G~0~ or G~2~ quiescence.

We found that Dap expression (1) initiates in a subset of dividing NSCs during embryogenesis and (2) induces these NSCs to enter G~0~ quiescence. These features show remarkable parallels with p57 expression and function in mammalian NSC quiescence. In the developing mouse brain, p57 expression increases in a subset of proliferating embryonic NSCs around E15.5, inducing them to enter G~0~ quiescence ([@bib18]). Once quiescent, p57-expressing NSCs are retained into the adult V-SVZ ([@bib17], [@bib18]). Intriguingly, p57 deletion in the developing mouse brain was shown to reduce, but not eliminate, the emergence of quiescent NSCs in the adult V-SVZ, suggesting that some NSCs in the mammalian brain do not require p57 for quiescence entry ([@bib18]). We found that ∼75% of NSCs do not express Dap in the *Drosophila* brain and that these NSCs later become quiescent in G~2~ instead of G~0~. The *p57*-independent NSCs in the mouse brain might be comparable to G~2~-quiescent NSCs in *Drosophila*.

In both mammals and *Drosophila*, NSCs are set aside to become quiescent during proliferative stages. Interestingly, Dap has been shown to induce a switch in NSC proliferation mode during *Drosophila* embryogenesis ([@bib2]). At cell division, most NSCs in the brain produce a ganglion mother cell (GMC) that divides once to generate two neurons and/or glia (type 1 proliferation). During mid-embryogenesis, Dap-expressing NSCs switch from type 1 proliferation to type 0 proliferation, in which the GMC differentiates directly into a post-mitotic cell without dividing ([@bib3], [@bib2], [@bib24]). It has been suggested that all NSCs express Dap during embryogenesis ([@bib2]). We now show that only a subset of embryonic NSCs, the G~0~ population, expresses Dap. We propose that Dap-expressing NSCs first switch from type 1 to type 0 proliferation at mid-embryogenesis, before undergoing G~0~ quiescence ([Figure 4](#fig4){ref-type="fig"}E). In contrast, Dap non-expressing NSCs remain in type 1 proliferation mode and undergo G~2~ quiescence ([Figure 4](#fig4){ref-type="fig"}E). A similar switch in NSC proliferation mode may also precede quiescence entry in the developing mammalian brain.

We have shown that the dorsal patterning factor Msh directly induces Dap expression in dorsal NSCs, causing them to enter G~0~ quiescence. The switch from G~0~ to G~2~ quiescence in *msh* mutants is less severe than in *dap* mutants, suggesting that Msh is one of the several regulators upstream of Dap expression. Indeed, Hox genes, Notch signaling, and temporal patterning factors have been shown to influence Dap expression in the brain ([@bib2], [@bib4], [@bib10], [@bib19]).

The distribution of G~0~- versus G~2~-quiescent NSCs along the dorsal-ventral brain axis is striking, given that G~2~-quiescent NSCs reactivate to produce neurons faster than G~0~ NSCs ([@bib34]). It is possible that ventral neurons must be generated first to direct dorsal neurons to form the correct neural circuits, in a role comparable to the pioneer neurons of the embryonic nervous system ([@bib21]). The dorsal-ventral patterning system is well conserved evolutionarily, and the homologs of Msh, Ind, and Vnd are also expressed in columns during mammalian brain development ([@bib42]). It is not known whether dorsal-ventral patterning controls *p57* expression in NSCs in the mammalian brain. However, MSX1, one of the Msh homologs, binds upstream of the *p57* locus in cultured mouse myoblasts ([@bib44]). Our finding that Msh directly induces *dap* expression in NSCs raises the possibility that dorsal-ventral control of p57/Dap and NSC quiescence is conserved in the mammalian brain.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Chicken polyclonal anti-β-galactosidaseabcamCat\# ab9361, RRID:[AB_307210](nif-antibody:AB_307210){#intref0010}Rabbit polyclonal anti-Cyclin A[@bib46]ID: rb270Rabbit polyclonal anti-DacapoC Lehner (University of Zurich, Switzerland)N/AGuinea pig anti-Deadpan[@bib6]N/ARat anti-DeadpanabcamCat\# ab195173,\
RRID:[AB_2687586](nif-antibody:AB_2687586){#intref0015}Guinea pig anti-Runt[@bib25]\#638Rat anti-WorniuabcamCat\# ab196362**Deposited Data***D. melanogaster* Release 6 Genome assemblyBerkeley Drosophila Genome Project; [@bib47]<https://www.ncbi.nlm.nih.gov/assembly/GCF_000001215.4>**Experimental Models: Organisms/Strains***D. melanogaster*: w^1118^Bloomington Drosophila Stock CentreBDSC Cat\# 3605, RRID:BDSC_3605*D. melanogaster*: P{PZ}dap04454Bloomington Drosophila Stock CentreBDSC Cat\# 11377, RRID:BDSC_11377*D. melanogaster*: Df(2R)Exel9016Bloomington Drosophila Stock CentreBDSC Cat\# 7867, RRID:BDSC_7867*D. melanogaster*: P{w^+mC^=lacW}dap^k07309^Bloomington Drosophila Stock CentreBDSC Cat\# 10406, RRID:BDSC_10406*D. melanogaster*: P{w^+mC^=wor.GAL4.A}2Bloomington Drosophila Stock CentreBDSC Cat\# 56553, RRID:BDSC_56553*D. melanogaster*: P{y^+t7.7^ v+^t1^.^8^=TRiP.HMS05362}attP40Bloomington Drosophila Stock CentreBDSC Cat\# 64026, RRID:BDSC_64026*D. melanogaster*: P{y^+t7.7^ v^+t1.8^=VALIUM20-mCherry}attP2Bloomington Drosophila Stock CentreBDSC Cat\# 35785, RRID:BDSC_35785*D. melanogaster*: P{y^+t7.7^ w^+mC^=GMR19B03-GAL4}attP2Bloomington Drosophila Stock CentreBDSC Cat\# 49830, RRID:BDSC_49830*D. melanogaster*: P{w^+mC^=UAS-RedStinger}4, P{w^+mC^=UAS-FLP.D}JD1, P{w^+mC^=Ubi-p63E(FRT.STOP)Stinger}9F6Bloomington Drosophila Stock CentreBDSC Cat\# 28280, RRID:BDSC_28280*D. melanogaster*: msh\[delta68\]Kyoto DGGRKyoto Cat\# 116970*D. melanogaster*: msh\[delta89-lacZ\]Kyoto DGGRKyoto Cat\# 116971*D. melanogaster*: vnd^6^F J Díaz-Benjumea (Centro de Biología Molecular Severo Ochoa, Spain)N/A*D. melanogaster*: UAST-LT3-NDam[@bib39]N/A*D. melanogaster*: UAST-LT3-NDam-MshThis paperN/A**Oligonucleotides**Primer: Dam-Msh-FWD-XhoI\
TCATCTCGAGATGTTAAAGCTCAGCCCAGCThis paperN/APrimer: Dam-Msh-REV-XbaI\
TCATTCTAGATTATCCCAGGTGCATCAGGCThis paperN/A**Recombinant DNA**Plasmid: pUASTattB-LT3-NDam[@bib39]N/APlasmid: pUASTattB-LT3-NDam-MshThis paperN/AcDNA: clone LD04235 (*msh*)*Drosophila* Genomics Resource CentreDGRC Cat\# 4281

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andrea H. Brand (<a.brand@gurdon.cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### *Drosophila melanogaster* Rearing and Genetics {#sec4.3.1}

*Drosophila melanogaster* were reared at 25°C except for RNAi experiments, which were conducted at 29°C. Embryos were collected onto yeasted apple juice plates and staged according to ([@bib5]). For larval experiments, larvae were transferred to a fresh, yeasted food plate within one hour of hatching (designated 0 hours after larval hatching (ALH)) and allowed to develop to the required stage. The following stocks were obtained from the Bloomington Drosophila Stock Centre: *w*^*1118*^, *dap*^*04454*^ (BL11377) ([@bib12], [@bib41]), *dap*^*Df9016*^ (BL7867), *dap*^*k07309*^ (*dap::lacZ*; BL10406) ([@bib40]), *wor*-GAL4 ([@bib1]), P{TRiP.HMS05362}attP40 (*dap* RNAi; BL64026), P{GMR19B03-GAL4}attP2 (*msh*-GAL4; BL49830), G-TRACE (BL28280) ([@bib16]), P{VALIUM20-mCherry}attP2 (*mCherry* RNAi; BL35785). The following stocks were obtained from the Kyoto *Drosophila* Stock Centre: *msh*^*Δ68*^ (116970) ([@bib20]), *msh*^*lacZ-Δ89*^ (*msh::lacZ*; 116971) ([@bib20]). *vnd*^*6*^ was a kind gift from Fernando Jiménez Díaz-Benjumea (Centro de Biología Molecular Severo Ochoa, Spain) ([@bib23]). UAST-LT3-NDam was published previously ([@bib39]). The following stock was generated for this study: UAST-LT3-NDam-Msh.

Method Details {#sec4.4}
--------------

### Antibody Staining {#sec4.4.1}

Embryos were washed into a nitex basket with water, dechorionated for 3 minutes in 50% bleach/water, then fixed for 20 minutes in 4% formaldehyde (in PBS)/heptane on a rolling shaker. Fixed embryos were stored in methanol at -20°C until use. For immunostaining: fixed embryos were re-hydrated in PBTx (0.3% Triton X-100/PBS), blocked for 15 minutes in 10% normal goat serum/PBTx, then incubated overnight with primary antibodies at 4°C. Primary antibodies were washed off with PBTx and replaced with secondary antibodies for 2 hours at room temperature, or overnight at 4°C. Secondary antibodies were washed off with PBTx and embryos were mounted in 50% glycerol/PBS.

Larval brains were dissected in PBS, then fixed for 20 minutes in 4% formaldehyde/PBS. Fixed brains were washed three times in PBTx, blocked for 15 minutes in 10% normal goat serum/PBTx, then immunostained as described for embryos. Larval brains were mounted in Vectashield mounting medium (Vector Laboratories).

The following primary antisera were used, diluted in PBTx: chicken anti-βgal 1:1,000 (abcam, ab9361), rabbit anti-CycA 1:500 (([@bib46]), rb270), rabbit anti-Dap 1:600 (gift from C. Lehner), guinea pig anti-Dpn 1:5,000 ([@bib6]), rat anti-Dpn 1:100 (abcam, 11D1BC7, ab195173), guinea pig anti-Run 1:200 ([@bib25], 638), rat anti-Wor 1:100 (abcam, 5A3AD2, ab196362). Primary antibodies were detected using Alexa Fluor-conjugated secondary antibodies (Thermo Fisher Scientific) diluted 1:500 in PBTx.

### Designation of 'Dorsal' and 'Ventral' in Confocal Microscopy Images {#sec4.4.2}

tVNCs were imaged in ventral view. The left-right axis in each image corresponds to medial-lateral in the tVNC. During *Drosophila* embryogenesis, ventral NSCs delaminate medially and dorsal NSCs delaminate laterally. Thus, the medial-lateral axis is labelled dorsal-ventral in confocal images.

### *dap* Mutant Analysis {#sec4.4.3}

The loss of function allele *dap*^*04454*^ was crossed to the genomic deficiency *dap*^*Df9016*^ and designated '*dap* mutant' throughout this study, as described in ([@bib2]).

### *dap* Knockdown in NSCs {#sec4.4.4}

*dap* RNAi was expressed in NSCs using *wor*-GAL4. Flies were raised at 29°C and assessed at 0ALH. To assess stem cell activation, dap RNAi (or control) larvae were transferred within 1 hour ALH to a new food plate and kept for a further 20 hours at 25°C. Brains were dissected at 20ALH, and co-stained for Dpn (to label NSCs) and Wor (to label activated NSCs).

### *msh*\>G-TRACE {#sec4.4.5}

G-TRACE was expressed in Msh-expressing NSCs using GMR19B03-GAL4. Flies were raised at 25°C and assessed at 0ALH. The image in [Figure 3](#fig3){ref-type="fig"}D depicts the 'historical expression' reporter from the G-TRACE cassette.

### Generation of UASTattB-LT3-NDam-Msh Flies for TaDa {#sec4.4.6}

Full length *msh* cDNA was PCR amplified from Clone LD04235 (DGRC Bloomington ID \#4281), with flanking XhoI and XbaI restriction sites, using the following primers:Dam-Msh-FWD-XhoI5'-TCATCTCGAGATGTTAAAGCTCAGCCCAGC-3'Dam-Msh-REV-XbaI5'-TCATTCTAGATTATCCCAGGTGCATCAGGC-3'

The amplified PCR product was digested with XhoI and XbaI enzymes and ligated into pUASTattB-LT3-NDam ([@bib39]), also digested with XhoI and XbaI, to generate pUASTattB-LT3-NDam-Msh.

Stable transgenic flies (UAST-LT3-NDam-Msh) were established by injecting pUASTattB-LT3-NDam-Msh into embryos expressing phiC31 integrase and carrying the attP2 genomic landing site on III. Successful transgenesis was confirmed by sequencing.

### Identification of Msh Genome-Wide Binding Targets Using TaDa {#sec4.4.7}

Msh targets were identified using TaDa ([@bib39]). *wor*-GAL4 flies were crossed to control (UAST-LT3-NDam) or test (UAST-LT3-NDam-Msh) flies. Embryos were collected onto apple juice plates for a two-hour period and developed at 25°C for 20 hours. Embryos were washed into a nitex basket using distilled water and dechorionated by swirling for three minutes in 50% bleach. Dechorionated embryos were washed well with distilled water, transferred to an Eppendorf tube, liquid removed and frozen at -80°C until ready for use. Three replicate experiments were conducted and ∼25μl of embryos were used for each replicate.

Genomic DNA was extracted from embryos using the QiaAmp DNA micro kit (Qiagen), as described previously in the TaDa protocol ([@bib32]). In brief, frozen embryos were re-suspended in PBS containing 110mM EDTA and 0.25μg of RNase A, then disrupted mechanically using an electric drill. 20μl of Proteinase K (QiaAmp DNA micro kit) were added, and the sample left for 1 minute at room temperature. 200μl of Buffer AL were added, the tube was inverted gently to mix and then incubated at 56°C overnight. The following day, the sample was cooled to room temperature and 200μl of 100% ethanol added. The sample was applied to a QiaAmp DNA micro kit spin column, then washed and centrifuged on the column with AW1 followed by AW2 solution. The column was transferred to a clean tube and centrifuged again to dry. Finally, the column was transferred to a clean tube and the genomic DNA eluted in 50μl of AE buffer. Genomic DNA was digested with DpnI enzyme (NEB) overnight at 37°C, ligated with DamID adaptors, then digested with DpnII enzyme. Adapted DNA was PCR amplified, sonicated and prepared for Illumina sequencing. TaDa sequencing data were aligned to *Drosophila* genome annotation release 6.

### Image Acquisition and Processing {#sec4.4.8}

Fluorescent images were acquired using a Leica SP8 confocal microscope. Images were analysed using Fiji software ([@bib36]). Images were processed for brightness and contrast using Adobe Photoshop. Msh binding data were visualised using Integrative Genomics Viewer (IGV) software ([@bib35]). Figures were compiled in Adobe Illustrator.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

NSCs in the tVNC of the *Drosophila* central nervous system were quantified throughout this study. Quantifications in the form 'NSCs per hemi-segment' are average values calculated by dividing the total number of NSCs in the tVNC by six (the number of hemi-segments in the tVNC). R was used for statistical analysis. Data were tested for assumptions of normality (Shapiro-Wilk test) and equality of variance (Levene's test). Statistical tests can be found in the relevant figure legends. Statistical significance was defined as *p*\<0.05. No data were excluded.

Supplemental Information {#app2}
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